Ensysce Biosciences Regains Nasdaq Equity Compliance – Minichart
Ensysce Biosciences (ENSC) has met Nasdaq's minimum equity requirement and requested a second 180-day grace period for its bid price. The company raised $21M from its Series C financing and awaits Nasdaq's confirmation. Delisting risk is reduced, but the second tranche is contingent on a clinical milestone.
How this was made
The 30-second read
Why it matters
Regaining equity compliance removes an immediate regulatory risk, but bid‑price deficiency remains.
Market read
Compliance news is material for ENSC investors and may influence micro‑cap sentiment.
What to watch
The second tranche of financing remains contingent on a clinical milestone, which could affect liquidity.
Background
Nasdaq requires $2.5 M equity and a $1.00 bid price; non‑compliance can trigger delisting.
Ticker impact
Ensysce Biosciences regained Nasdaq equity compliance and requested a second 180‑day bid‑price grace period, reducing immediate delisting risk.
Modest upside as investors reassess delisting risk.
The company now meets the $2.5 M equity floor and seeks additional time to fix bid‑price deficiency, a material corporate‑action for a micro‑cap.
Market effects
Sets a precedent for other small‑cap biotech firms facing Nasdaq compliance issues.
Limited to US Nasdaq micro‑cap segment.
Low; primarily affects ENSC shareholders.
Counterpoint
If Nasdaq denies the grace period, the stock could face a sharp decline.
Key entities
- companyEnsysce Biosciences
Biotech firm listed on Nasdaq (ENSC).
